Drug Database
TE

temozolomide (SI 053 / Temodex / SI053)

✓ Approved

Double Bond Pharmaceutical · 小分子 · 小分子

什么是 temozolomide?

temozolomide 是一种小分子,由Double Bond Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Intratumoral Injection。

药物档案

商品名SI 053, Temodex, SI053
公司Double Bond Pharmaceutical
药物类别小分子
给药途径Intratumoral Injection
状态Approved

治疗适应症

temozolomide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Brain neoplasm malignant✓ Approved

相关研究文献

PubMedPediatric blood & cancer2026-11-18

Recommended Phase 2 Dose for Abemaciclib in Combination With Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results From Study JPCS Part B.

Lassaletta Alvaro A, Moreno Lucas L, Arakawa Ayumu A, Thorwarth Anne A et al.

Cyclin-dependent kinase 4/6 (CDK4/6) pathway aberrations, including CDK4 or CCND1 amplification, CDKN2A/B loss, retinoblastoma (RB) dysregulation, and cyclin D overexpression, are relevant for pediatric cancers. Abemaciclib, a selective CDK4/6 inhibitor with preferential CDK4 activity and central nervous system (CNS) penetration, induces sustained G1 arrest. Preclinical pediatric models show additive or synergistic activity with temozolomide, supporting further evaluation. Here, the recommended Phase 2 dose (RP2D) for abemaciclib with temozolomide is defined in children and young adults with relapsed/refractory solid tumors. JPCS Part B was an open-label, multicenter Phase 1b study using a 3 + 3 design to evaluate continuous abemaciclib (70-115 mg/m2 orally BID) with temozolomide (100-150 mg/m2 orally days 1-5) in 21-day cycles. The primary objective was RP2D determination based on dose-limiting toxicities (DLTs) and pharmacokinetics. Secondary objectives included safety and antitumor activity. Twenty-six patients (median age 11 years; range, 1-18) with heavily pretreated relapsed/refractory tumors were enrolled. The RP2D was established as 115 mg/m2 abemaciclib BID on Days 1-21, with 150 mg/m2 temozolomide on Days 1-5 of 21-day cycles, based on two DLTs (thrombocytopenia), one at the RP2D. The maximum tolerated dose was not reached. Toxicities reflected expected myelosuppression and predominantly low-grade gastrointestinal events. Together, 35% and 19% of patients experienced Grades 3 and 4 treatment-related toxicities, respectively. Steady-state abemaciclib concentrations aligned with adult efficacy-associated ranges, with no drug-drug interactions. Three patients (12%) achieved partial responses and 10 (38%) stable disease, yielding 50% disease control. Three patients had sustained disease control with >6 months on treatment. Abemaciclib plus temozolomide is feasible and well-tolerated and shows preliminary antitumor activity, supporting further evaluation in Phase 2 trials. NCT04238819.

PMID 43049245
阅读全文 →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-11-18

Chromatin Remodeling of RasGRP3 Underlies Temozolomide Sensitivity in Glioblastoma Organoids.

Chen Bohan B, Su Guangsong G, Huang Yiting Y, Liu Rong R et al.

Acquired resistance to temozolomide (TMZ) constitutes a formidable clinical barrier in the management of glioblastoma (GBM). GBM organoid models (GBO) that faithfully mirror the parental tumor phenotype serve as powerful research instruments to overcome the limitations in this field. We established GBOs derived from primary glioma patients and their TMZ low-sensitivity counterparts. To unravel the intricate molecular underpinnings of this process, we performed an unbiased, integrated multi-omics analysis encompassing epigenomic, 3D genomic, and transcriptomic profiling, coupled with dual CRISPR interference (CRISPRi) screening of TMZ-induced enhancers (TiEns) and their cognate target genes. Our findings demonstrate that enhancer-mediated 3D chromatin remodeling drives chemosensitivity predominantly by transcriptionally activating drug-sensitivity-associated genes, such as RasGRP3, VEGFA, BTN3A2, etc. Knockdown or knockout of these genes and enhancers renders glioma cells more sensitive to TMZ, especially RasGRP3. Our work unveils a druggable "enhancer-chromatin-target" signaling axis and proposes a novel combinatorial therapeutic strategy to surmount TMZ low sensitivity in GBM.

PMID 43052008
阅读全文 →
PubMedChembiochem : a European journal of chemical biology2026-11-18

Glioblastoma-Neuroblastoma Cocultured Multicellular Spheroid Model for Evaluating Temozolomide Response.

Murugappan Sivasubramanian S, Mali Ajay A, Sandbhor Puja P, Thorat Nanasaheb N

Glioblastoma is the most lethal primary brain tumor, and its resistance to therapy is increasingly understood to arise not from tumor cells alone but also from their integration into the surrounding neural circuitry. However, no existing preclinical spheroid model isolates the direct effect of neuronal-lineage cells on glioblastoma's drug response within a rapid, scalable 3D system. We developed a heterotypic 3D coculture spheroid combining glioblastoma (U87-MG) with a neuronal-lineage surrogate population (SH-SY5Y) via the agarose liquid overlay method to directly understand this gap. Subsequently, growth, morphology, hypoxia, and temozolomide (TMZ) response over 14 days against glioblastoma only and neuroblastoma only spheroids were characterized. The coculture adopted a glioblastoma like compact, chemoresistant architecture yet, contrary to what this architecture alone would predict, it showed measurable chemosensitivity at every TMZ concentration tested, including 10 µM, a dose at which neither monoculture responded at all. This indicates that the neuronal-lineage surrogate population alters the overall TMZ response of the coculture spheroids. Drug-response data from glioblastoma only models may therefore not reflect true tumor behavior in the presence of neuronal-lineage cells, supporting the inclusion of neuronal-lineage surrogate components in preclinical glioblastoma drug screening.

PMID 43049271
阅读全文 →
PubMedAnnals of African medicine2026-11-18

Electroconvulsive Therapy in a Patient with Schizophrenia and Coexisting Right Frontoparietal Neoplastic Lesion: A Case Report with Literature Review.

Tennety Vikramaditya V, Patil Sandeep S

Co-occurrence of primary brain tumors and schizophrenia presents diagnostic and therapeutic challenges. Electroconvulsive therapy (ECT) has historically been considered contraindicated in patients with intracranial lesions. A 27-year-old female with an 11-year history of schizophrenia presented with worsening psychosis, irritability, and aggression. She was previously diagnosed with diffuse midline glioma, which was inoperable and treated with temozolomide. Due to partial response to amisulpride, she received four sessions of modified ECT (mECT) following a multidisciplinary evaluation ruling out intracranial hypertension. The treatment was well-tolerated with rapid reduction in psychotic symptoms, agitation, and aggression, without neurological deterioration or seizure-related complications. Thus, this case demonstrates that mECT can be safely administered in select patients with schizophrenia and co-occurring high-grade glioma, challenging historical contraindications. Early neuroimaging is essential in treatment-resistant or atypical psychosis to exclude underlying structural pathology.

PMID 43049155
阅读全文 →
PubMedNeuro-oncology practice2026-11-18

Efficacy of vorasidenib for patients with IDH-mutant glioma previously treated with ivosidenib.

Schultz Sydney E SE, Barreto Jason N JN, Mead-Harvey Carolyn C, Caron Samantha J SJ et al.

Isocitrate dehydrogenase-1 (IDH-1) inhibitor ivosidenib and dual-IDH1/2 inhibitor vorasidenib have demonstrated clinical activity in the treatment of IDH-mutant gliomas. We evaluated the efficacy of vorasidenib in patients with prior exposure to ivosidenib. Retrospective review of patients with IDH-mutant glioma treated with vorasidenib who had prior treatment with ivosidenib. Previous treatments, radiographic response, and adverse events were collected and analyzed descriptively. Twenty-nine patients (median age 42, 34% female) were evaluated. Tumor types included IDH-mutant astrocytoma (grade 2 n = 9, 31%; grade 3 n = 3, 10%; grade 4 n = 3, 10%) and oligodendroglioma (grade 2 n = 10, 34%; grade 3 n = 4, 14%). Treatments received prior to ivosidenib included surgical resection (n = 23, 79%), radiation (n = 16, 55%), temozolomide (n = 15, 52%), procarbazine, lomustine, vincristine (PCV, n = 2, 7%), bevacizumab (n = 3, 10%), lomustine (n = 2, 7%), and pembrolizumab (n = 1, 3%). Four patients received additional treatment in between ivosidenib and vorasidenib treatment.Ten of 16 (63%) patients who experienced disease progression on ivosidenib achieved stable disease and remain on vorasidenib, while 6 (37%) had continued progression. Eleven patients with stable disease on ivosidenib transitioned to vorasidenib following FDA approval and remained without progression. Two patients who transitioned to vorasidenib due to ivosidenib-related adverse effects (diarrhea and fatigue) experienced symptom resolution and maintained disease stability. Vorasidenib demonstrated clinical efficacy in patients with IDH-mutant gliomas previously treated with ivosidenib. Notably, stable patients who transitioned maintained disease stability, while some of those with progressive disease achieved stabilization with vorasidenib. These findings support vorasidenib as a viable therapeutic option following ivosidenib exposure.

PMID 43047530
阅读全文 →
PubMedACS pharmacology & translational science2026-11-18

Pharmacological Study of Novel Small-Molecule Inhibitors Targeting B‑Cell Lymphoma 9/β-Catenin in the Treatment of Glioma.

Li Huiyu H, Lu Xiaoxuan X, He Yangbo Y, Chen Gang G et al.

Glioblastoma (GBM), one of the most aggressive and lethal primary brain tumors, remains a major challenge in neuro-oncology. The Wingless/Int-1 (Wnt)/β-catenin pathway has emerged as a potential therapeutic target for gliomas. However, owing to the lack of small-molecule inhibitors targeting B-cell lymphoma 9 (BCL9), a coactivator of β-catenin, the therapeutic potential of BCL9 in GBM has not been pharmacologically validated. Here, we report a novel small-molecule inhibitor of the BCL9/β-catenin interaction, designated ZD37-28R. Molecular docking suggested that ZD37-28R binds to β-catenin with high affinity. In vitro, ZD37-28R disrupted the interaction between BCL9 and β-catenin, markedly inhibited β-catenin-dependent transcriptional activity, and reduced the proliferation and migration of U87-MG and U251 GBM cells. Oil Red O staining and fluorescence-activated cell sorting further showed that ZD37-28R decreased lipid accumulation and lipid reactive oxygen species in GBM cells. These effects were associated with reduced expression of sterol regulatory element-binding protein 1 (SREBP1), a key regulator of lipid metabolism, thereby further impairing the viability and migration of glioma cells. In a subcutaneous glioma model, ZD37-28R exhibited robust antitumor activity with low toxicity. In an orthotopic glioma model, ZD37-28R showed antitumor efficacy and enhanced the effect of temozolomide (TMZ), as evaluated by magnetic resonance imaging. Taken together, our study identifies ZD37-28R as a novel BCL9/β-catenin inhibitor and suggests that it may represent a promising lead compound for GBM treatment, particularly in combination with TMZ.

PMID 43048461
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多temozolomide